Cell Line News and Research

RSS

New drug combination may be effective against malignant melanoma

A team of Massachusetts General Hospital investigators has discovered a new combination of drugs that may be effective against one of the deadliest cancers, malignant melanoma. The combination - pairing a drug targeted against mutations in the BRAF gene with a second drug that targets another important signaling pathway - was discovered through one of the largest screens of cancer drug combinations conducted to date.

27 Oct 2015

Sinovac Dalian receives approval to start human clinical trials of varicella vaccine candidate

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, today announced that one of its subsidiaries, Sinovac Dalian, has received approval to begin human clinical trials on its varicella vaccine candidate. The clinical trial application for the varicella vaccine was officially accepted by the China Food and Drug Administration in January 2013.

26 Oct 2015

Orange pigment may have potential as anti-cancer drug

An orange pigment found in lichens and rhubarb called parietin may have potential as an anti-cancer drug, scientists at Winship Cancer Institute of Emory University have discovered.

20 Oct 2015

Penn researchers lay groundwork for developing lncRNA-based tools for new cancer treatment

Growing insights about a significant, yet poorly understood, part of the genome - the "dark matter of DNA" -- have fundamentally changed the way scientists approach the study of diseases.

13 Oct 2015

Researchers describe unknown mechanism behind progeria

Progeria, a premature aging disease, is the research focus of Roland Foisner's team at the Max F. Perutz Laboratories of the University of Vienna and the Medical University of Vienna. Children suffering from progeria die at an average age of 14 to 15 years, often from heart attacks and strokes.

7 Oct 2015

Novel technique may help women and their oncologists choose options for treating breast cancer

Biomedical engineers have demonstrated a proof-of-principle technique that could give women and their oncologists more personalized information to help them choose options for treating breast cancer.

6 Oct 2015

Cancer-causing gene disrupts internal rhythm, metabolic pathways in cancer cells

Myc is a cancer-causing gene responsible for disrupting the normal 24-hour internal rhythm and metabolic pathways in cancer cells, found a team led by researchers from the Perelman School of Medicine at the University of Pennsylvania. Postdoctoral fellow Brian Altman, PhD, and doctoral student Annie Hsieh, MD, both from the lab of senior author Chi Van Dang, MD, PhD, director Abramson Cancer Center, study body clock proteins associated with cancer cells.

18 Sep 2015

Exosomes provide a promising way to induce human stem cell differentiation

Regenerative medicine using stem cells is an increasingly promising approach to treat many types of injury. Transplanted stem cells can differentiate into just about any other kind of cell, including neurons to potentially reconnect a severed spinal cord and repair paralysis.

16 Sep 2015

Three drug-like compounds may offer better odds of survival to patients with prostate cancer, find SMU researchers

Researchers at Southern Methodist University, Dallas, have discovered three new drug-like compounds that could ultimately offer better odds of survival to prostate cancer patients.

9 Sep 2015

CEVEC launches unique cell-expression system for scalable production of gene therapy vectors

CEVEC Pharmaceuticals GmbH, the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, today announced the introduction of its unique cell-expression system, CAP GT, for the fully scalable production of gene therapy vectors, based on the Company's proprietary CAP technology.

8 Sep 2015

Penn researchers identify viral products that trigger immune response against RSV infection

Almost all human beings are exposed to the respiratory syncytial virus, or RSV, before their second birthdays. For most, the symptoms mimic those of the common cold: runny nose, coughing, sneezing, fever.

4 Sep 2015

Cells expressing faulty CFTR channel to TNF-α can 'fix' cystic fibrosis cells

Scientific experiments examining what happens to the faulty channel protein that causes cystic fibrosis during inflammation have yielded unexpected and exciting results. The study, conducted by Sara Bitam and her colleagues at INSERM in France, has just passed peer review on open science publishing platform F1000Research.

3 Sep 2015

Treating cancer cells with quizartinib inhibits key metabolic pathway, activates macroautophagy

A study published in The Journal of Cell Biology describes a way to force cancer cells to destroy a key metabolic enzyme they need to survive.

1 Sep 2015

CMC Biologics, PATH Malaria Vaccine Initiative sign agreement for development of specific monoclonal antibodies

CMC Biologics, a global leader in clinical and commercial development and contract manufacture of therapeutic proteins, announced today it has entered into an agreement with the PATH Malaria Vaccine Initiative (MVI) for process development and manufacture of specific monoclonal antibodies to test for their capacity to protect humans from malaria infection.

12 Aug 2015

Engineered protein shown effective in patients with severe von Willebrand disease

The first protein engineered to help control bleeding episodes in patients with severe von Willebrand disease (vW disease) has been shown to be safe and effective, according to results of a Phase III trial.

4 Aug 2015

New tool combines drugs to target kinase dependency in cancer

Targeted therapies attack a cancer's genetic sensitivities. However, it can be difficult to discover the genetics driving a patient's cancer, and the effects of drugs designed to target a genetic abnormality often go beyond their intended target alone. The result is threefold: sometimes a drug is prescribed to treat a target that proves to be irrelevant to the disease, sometimes an existing drug could be used to treat a cancer for which there is no approved targeted therapy, and sometimes a combination of targeted treatments could be used to simultaneously silence more than one genetic cause of a patient's cancer.

29 Jul 2015

Ebola vaccine study begins in Dakar, Senegal

A trial to evaluate an Ebola vaccine has begun in Dakar, Senegal, after initial immunisations started at the Jenner Institute, Oxford University. The announcement comes as a conference in Oxford discusses the global response to Ebola and the implications for future drug and vaccine development.

15 Jul 2015

Neuralstem's HK532-IGF-1 neural stem cells therapy for Alzheimer's disease presented at ISSCR Annual Meeting

Neuralstem, Inc., a biopharmaceutical company using neural stem cell technology to develop small molecule and cell therapy treatments for central nervous system diseases, announced that the poster "Human Neural Stem Cells Expressing IGF-1: A Novel Cellular Therapy for Alzheimer's Disease" was presented yesterday at the International Society for Stem Cell Research (ISSCR) Annual Meeting in Stockholm, Sweden.

27 Jun 2015

Novogen’s chemotherapy drug Anisina proves as effective anti-cancer agent in animals

US-Australian drug discovery company, Novogen Limited announced today that its candidate cytotoxic chemotherapy drug, Anisina, has proved an effective anti-cancer agent in animals, the result of which it now has been fast-tracked by the Company to come into the clinic.

24 Jun 2015

Scientists identify novel mechanism that can reorganize cell's genetic architecture to promote senescence

Senescence, a phenomenon in which cells cease to divide and grow, can be caused by everything from natural DNA damage to treatment with chemotherapy. However, several mechanisms allow for cells to bypass senescence and grow out of control, eventually becoming cancerous.

3 Jun 2015